XposeALI: ISAB names its 3D in vitro cell exposure module
ISAB has named the 3D in vitro cell exposure module of its PreciseInhale system XposeALI, in response to growing interest from environmental and toxicological researchers. The new name underlines the unique Air Lifted Interface technology at the heart of the module.
Inhalation Sciences’ in vitro model, now named XposeALI, is unique in combining aerosol capability with 3D cell models cultured in an Air Liquid Interface (ALI.) This delivers voluminous and precise data, and closely mimics in vivo conditions. The unique combination is possible because XposeALI works as a module of ISAB’s dry powder testing system PreciseInhale.
Inhalation Sciences’ founder and CSO Dr Per Gerde: “Combining aerosol capability and unique 3D-models with primary bronchial epithelial cells cultured in ALI is unique, and the technology continues to develop successfully. We’re confident it will play an even greater role in cell culturing research in the future.”
The dynamic advantage
ISAB CEO Fredrik Sjövall says: “Even our nearest competitors in cell exposures have limitations that we overcome by combining ALI with our dry powder aerosolization platform PreciseInhale. Limited in handling dry powders, they primarily use nebulized droplets instead – so they are unlikely to achieve the deposition quality XposeALI delivers. Today these competing technologies essentially generate static PK data, not dynamic data that includes Cmax and Tmax curves, as ours does. XposeALI is still in development but maturing rapidly and earning a great deal of recognition.”
With research into the behavior and effects of environmental airborne particles and nanoparticles intensifying, the module is attracting growing Corporate Research interest from environmental researchers. In 2014 the system was successfully used by an environmental research team at Sweden’s Karolinska Institutet of environmental medicine, for research into nanoparticles from catalysts.
Cost benefits
Scarcity of test material and the need for respirable aerosol is an acute problem for environmental researchers studying toxic airborne particles. Whether collected from the environment or manufactured in a lab, study materials are nearly always expensive. Even with industrial granular materials, selecting the minuscule fraction that is actually respirable is highly costly. Because XposeALI works as a module of PreciseInhale it offers environmental researchers significant cost savings. PreciseInhale produces realistic aerosol exposures from minute amounts of collected / available study materials. The system typically uses between 50 – 100 mg of test substance for a full PK study, delivering accurate and detailed data exceptionally cost-effectively.
After working with the system in 2014, Lena Palmberg, Associate Professor, lung and airway research Karolinska Institutet, Sweden, said: “Cost-effective and very precise, Inhalation Sciences’ in vitro cell exposure system gives toxicologists and environmental researchers precise results that closely mirror in vivo.”
XposeALI: ISAB names its 3D in vitro cell exposure module
ISAB has named the 3D in vitro cell exposure module of its PreciseInhale system XposeALI, in response to growing interest from environmental and toxicological researchers. The new name underlines the unique Air Lifted Interface technology at the heart of the module.
Inhalation Sciences’ in vitro model, now named XposeALI, is unique in combining aerosol capability with 3D cell models cultured in an Air Liquid Interface (ALI.) This delivers voluminous and precise data, and closely mimics in vivo conditions. The unique combination is possible because XposeALI works as a module of ISAB’s dry powder testing system PreciseInhale.
Inhalation Sciences’ founder and CSO Dr Per Gerde: “Combining aerosol capability and unique 3D-models with primary bronchial epithelial cells cultured in ALI is unique, and the technology continues to develop successfully. We’re confident it will play an even greater role in cell culturing research in the future.”
The dynamic advantage
ISAB CEO Fredrik Sjövall says: “Even our nearest competitors in cell exposures have limitations that we overcome by combining ALI with our dry powder aerosolization platform PreciseInhale. Limited in handling dry powders, they primarily use nebulized droplets instead – so they are unlikely to achieve the deposition quality XposeALI delivers. Today these competing technologies essentially generate static PK data, not dynamic data that includes Cmax and Tmax curves, as ours does. XposeALI is still in development but maturing rapidly and earning a great deal of recognition.”
With research into the behavior and effects of environmental airborne particles and nanoparticles intensifying, the module is attracting growing Corporate Research interest from environmental researchers. In 2014 the system was successfully used by an environmental research team at Sweden’s Karolinska Institutet of environmental medicine, for research into nanoparticles from catalysts.
Cost benefits
Scarcity of test material and the need for respirable aerosol is an acute problem for environmental researchers studying toxic airborne particles. Whether collected from the environment or manufactured in a lab, study materials are nearly always expensive. Even with industrial granular materials, selecting the minuscule fraction that is actually respirable is highly costly. Because XposeALI works as a module of PreciseInhale it offers environmental researchers significant cost savings. PreciseInhale produces realistic aerosol exposures from minute amounts of collected / available study materials. The system typically uses between 50 – 100 mg of test substance for a full PK study, delivering accurate and detailed data exceptionally cost-effectively.
After working with the system in 2014, Lena Palmberg, Associate Professor, lung and airway research Karolinska Institutet, Sweden, said: “Cost-effective and very precise, Inhalation Sciences’ in vitro cell exposure system gives toxicologists and environmental researchers precise results that closely mirror in vivo.”
ISAB CEO Fredrik Sjövall says: “Even our nearest competitors in cell exposures have limitations that we overcome by combining ALI with our dry powder aerosolization platform PreciseInhale. Limited in handling dry powders, they primarily use nebulized droplets instead – so they are unlikely to achieve the deposition quality XposeALI delivers. Today these competing technologies essentially generate static PK data, not dynamic data that includes Cmax and Tmax curves, as ours does. XposeALI is still in development but maturing rapidly and earning a great deal of recognition.”
